间充质干细胞治疗自身免疫性疾病:未来展望

G. Pennesi
{"title":"间充质干细胞治疗自身免疫性疾病:未来展望","authors":"G. Pennesi","doi":"10.15406/icpjl.2018.06.00185","DOIUrl":null,"url":null,"abstract":"Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mesenchymal stem cell therapy for autoimmune diseases: future Perspectives\",\"authors\":\"G. Pennesi\",\"doi\":\"10.15406/icpjl.2018.06.00185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.\",\"PeriodicalId\":92215,\"journal\":{\"name\":\"International clinical pathology journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International clinical pathology journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/icpjl.2018.06.00185\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International clinical pathology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/icpjl.2018.06.00185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

为治疗目的移植到受体生物体中的间充质干细胞(MSC)不仅通过细胞间接触发挥作用,还通过分泌可溶性因子发挥作用。由于生物学问题和监管限制阻碍了MSC用于临床目的,因此应尝试新的方法。在过去的几年里,使用MSC衍生的微泡作为携带耐受性分子的潜在介质的可行性已经在自身免疫性疾病的临床前模式中进行了测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mesenchymal stem cell therapy for autoimmune diseases: future Perspectives
Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信